Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584389 | 0.81 | TAAR1 (0.41) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL5609990 | 0.80 | TAAR1 (0.39) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL95233 | 0.79 | — | — | |
| SCHEMBL3300692 | 0.79 | MPO (0.47) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL7052559 | 0.79 | TAAR1 (0.48) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL7500694 | 0.78 | TAAR1 (0.39) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL283845 | 0.77 | TAAR1 (0.41) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL146632 | 0.77 | RIPK1 (0.36) | IDO1CES2CES1RIPK1GPR84 | |
| SCHEMBL17552658 | 0.77 | TAAR1 (0.41) | IDO1TAAR1CES2BCHECES1 | |
| SCHEMBL214409 | 0.77 | TAAR1 (0.52) | IDO1TAAR1CES2BCHECES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | claimed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | claimed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | claimed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | claimed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| WO-2021224865-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | claimed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| EP-1981877-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2008-10-22 | — | — | EP | claimed |
| US-7411073-B2 | Selective non-steroidal glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | claimed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| WO-2007091703-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | WO | claimed |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | MERCK SHARP & DOHME CORP. | 2006-04-06 | — | — | US | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC6, HDAC5 | IDO1 2064/4885TAAR1 3104/4885CES2 1256/4885 |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | IDO1 2392/4885TAAR1 4166/4885CES2 234/4885 |
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | IDO1 2892/4885TAAR1 3142/4885CES2 1496/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | IDO1 2392/4885TAAR1 4166/4885CES2 234/4885 |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | IDO1 2392/4885TAAR1 4166/4885CES2 234/4885 |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | IDO1 2892/4885TAAR1 3142/4885CES2 1496/4885 |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | NR3C1, NR3C2, NR5A1 | IDO1 1481/4885TAAR1 908/4885CES2 4212/4885 |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | IDO1 2892/4885TAAR1 3142/4885CES2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.